AU2017291321B2 - Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties - Google Patents

Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties Download PDF

Info

Publication number
AU2017291321B2
AU2017291321B2 AU2017291321A AU2017291321A AU2017291321B2 AU 2017291321 B2 AU2017291321 B2 AU 2017291321B2 AU 2017291321 A AU2017291321 A AU 2017291321A AU 2017291321 A AU2017291321 A AU 2017291321A AU 2017291321 B2 AU2017291321 B2 AU 2017291321B2
Authority
AU
Australia
Prior art keywords
polypeptide
amino acid
linker
scil
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017291321A
Other languages
English (en)
Other versions
AU2017291321A1 (en
Inventor
Juan C. Alvarez
Heather C. Losey
Demetri T. Moustakas
Mark N. Namchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of AU2017291321A1 publication Critical patent/AU2017291321A1/en
Application granted granted Critical
Publication of AU2017291321B2 publication Critical patent/AU2017291321B2/en
Priority to AU2020204457A priority Critical patent/AU2020204457A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2017291321A 2016-06-22 2017-06-22 Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties Ceased AU2017291321B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020204457A AU2020204457A1 (en) 2016-06-22 2020-07-03 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353478P 2016-06-22 2016-06-22
US62/353,478 2016-06-22
PCT/US2017/038747 WO2018005226A2 (en) 2016-06-22 2017-06-22 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020204457A Division AU2020204457A1 (en) 2016-06-22 2020-07-03 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Publications (2)

Publication Number Publication Date
AU2017291321A1 AU2017291321A1 (en) 2018-12-13
AU2017291321B2 true AU2017291321B2 (en) 2020-06-18

Family

ID=60674961

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017291321A Ceased AU2017291321B2 (en) 2016-06-22 2017-06-22 Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
AU2020204457A Abandoned AU2020204457A1 (en) 2016-06-22 2020-07-03 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020204457A Abandoned AU2020204457A1 (en) 2016-06-22 2020-07-03 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Country Status (6)

Country Link
US (2) US10335459B2 (enExample)
EP (1) EP3474884A4 (enExample)
JP (1) JP7084881B2 (enExample)
AU (2) AU2017291321B2 (enExample)
CA (1) CA3026393C (enExample)
WO (1) WO2018005226A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015171965A2 (en) 2014-05-07 2015-11-12 Applied Molecular Transport Llc Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US9090691B2 (en) 2010-09-15 2015-07-28 Applied Molecular Transport Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US20160175458A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
EP3474884A4 (en) 2016-06-22 2020-08-19 Alkermes, Inc. COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10
KR20210005602A (ko) * 2018-03-23 2021-01-14 가비쉬-가릴리 바이오 어플리케이션스 리미티드. 막-결합된 IL-10을 발현하는 유전자 리프로그래밍된 Treg
KR20210110294A (ko) 2018-11-07 2021-09-07 어플라이드 몰레큘라 트랜스포트 인크. 통과세포외배출용 전달 구조체 및 관련 방법
EP3927728A2 (en) 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
WO2021034727A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
SI4065585T1 (sl) 2019-11-25 2025-11-28 Alkermes, Inc. Substituirane makrociklične spojine ter z njimi povezani postopki zdravljenja
US20230103554A1 (en) * 2020-04-03 2023-04-06 Baylor College Of Medicine TNFa SIGNALING TRIGGERS TUMOR-PROMOTING INFLAMMATION THAT CAN BE TARGETED TO THERAPY
MX2022014239A (es) * 2020-05-12 2023-02-09 Regeneron Pharma Nuevos agonistas de il10 y metodos para su uso.
WO2021243057A1 (en) * 2020-05-28 2021-12-02 The Board Of Trustees Of The Leland Stanford Junior University Engineered interleukin-10 polypeptides and uses thereof
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
EP4612165A1 (en) * 2022-11-02 2025-09-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2024144336A1 (ko) * 2022-12-30 2024-07-04 주식회사 프로젠 신규 이중 특이성 융합단백질 및 그의 용도
TW202502807A (zh) * 2023-06-02 2025-01-16 美商新舍凱公司 融合il10多肽

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428985B1 (en) * 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US20130316404A1 (en) * 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10
US20130336925A1 (en) * 2012-06-08 2013-12-19 Alkermes, Inc. Fusion Polypeptides Comprising Mucin-Domain Polypeptide Linkers
WO2015017548A2 (en) * 2013-07-31 2015-02-05 Amgen Inc. Stabilization of fc-containing polypeptides
WO2016100788A1 (en) * 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
JP2002530066A (ja) 1998-11-19 2002-09-17 スミスクライン・ビーチャム・コーポレイション Ｒｈａｍｍアンタゴニスト抗体
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
AU2001231532A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2008140595A2 (en) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Synthetic trivalent haptens, complexes thereof, and uses therefor
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
EP2519544A1 (en) * 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
AU2011226992B2 (en) 2010-05-10 2012-03-22 Ascend Biopharmaceuticals Pty Ltd Immunostimulatory and vaccine compositions
CN101962413B (zh) 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
PT2748201T (pt) 2011-08-23 2018-02-08 Roche Glycart Ag Moléculas de ligação ao antigénio biespecíficas que ativam as células t
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
AU2013293092A1 (en) 2012-07-23 2015-02-26 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
MA20150232A1 (fr) * 2012-08-08 2015-07-31 Roche Glycart Ag Protéines de fusion de l'interleukine-10 et leurs utilisations
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
AU2014257123A1 (en) 2013-04-24 2015-10-15 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
EP3102594A1 (en) 2014-02-06 2016-12-14 F. Hoffmann-La Roche AG Interleukine 10 immunoconjugates
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3474884A4 (en) 2016-06-22 2020-08-19 Alkermes, Inc. COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428985B1 (en) * 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US20130316404A1 (en) * 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10
US20130336925A1 (en) * 2012-06-08 2013-12-19 Alkermes, Inc. Fusion Polypeptides Comprising Mucin-Domain Polypeptide Linkers
WO2015017548A2 (en) * 2013-07-31 2015-02-05 Amgen Inc. Stabilization of fc-containing polypeptides
WO2016100788A1 (en) * 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
2016100788YOON, Sung Il, et al., Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. J. Biol. Chem. 2006, vol. 281, No 46, pages 35088-35096 *

Also Published As

Publication number Publication date
CA3026393C (en) 2023-03-14
AU2017291321A1 (en) 2018-12-13
WO2018005226A3 (en) 2018-04-05
US20190336582A1 (en) 2019-11-07
US11534480B2 (en) 2022-12-27
JP7084881B2 (ja) 2022-06-15
JP2019527200A (ja) 2019-09-26
NZ748787A (en) 2021-06-25
EP3474884A4 (en) 2020-08-19
CA3026393A1 (en) 2018-01-04
AU2020204457A1 (en) 2020-07-23
WO2018005226A2 (en) 2018-01-04
US10335459B2 (en) 2019-07-02
EP3474884A2 (en) 2019-05-01
US20170368144A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
US11534480B2 (en) Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
AU2018247255B2 (en) Single chain fc fusion proteins
DK2604693T3 (en) Single-chain TNFSF molecules
JP2024026738A (ja) 免疫調節融合タンパク質
US8338569B2 (en) FGFR extracellular domain acidic region muteins
AU2020291942A1 (en) Novel interleukin-2 variants for the treatment of cancer
CN108948207A (zh) 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
JP2023096044A (ja) 免疫調節融合タンパク質
JP2023554097A (ja) 二機能性抗ｐｄ１／ｉｌ－７分子
US20230303648A1 (en) Bifunctional molecules comprising an il-7 variant
NZ748787B2 (en) Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
US20240252601A1 (en) Ace2 fusion proteins and uses thereof
EP4359429A1 (en) Interleukin 15 variants
CN117597356A (zh) 基于白细胞介素-15的免疫细胞因子
HK1242337B (en) Single chain fc fusion proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired